These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 15867366

  • 1. Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer.
    Kim SJ, Uehara H, Yazici S, He J, Langley RR, Mathew P, Fan D, Fidler IJ.
    Cancer Res; 2005 May 01; 65(9):3707-15. PubMed ID: 15867366
    [Abstract] [Full Text] [Related]

  • 2. Simultaneous blockade of platelet-derived growth factor-receptor and epidermal growth factor-receptor signaling and systemic administration of paclitaxel as therapy for human prostate cancer metastasis in bone of nude mice.
    Kim SJ, Uehara H, Yazici S, Langley RR, He J, Tsan R, Fan D, Killion JJ, Fidler IJ.
    Cancer Res; 2004 Jun 15; 64(12):4201-8. PubMed ID: 15205332
    [Abstract] [Full Text] [Related]

  • 3. Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice.
    Kim SJ, Uehara H, Karashima T, Shepherd DL, Killion JJ, Fidler IJ.
    Clin Cancer Res; 2003 Mar 15; 9(3):1200-10. PubMed ID: 12631626
    [Abstract] [Full Text] [Related]

  • 4. Dual inhibition of the epidermal growth factor and vascular endothelial growth factor phosphorylation for antivascular therapy of human prostate cancer in the prostate of nude mice.
    Yazici S, Kim SJ, Busby JE, He J, Thaker P, Yokoi K, Fan D, Fidler IJ.
    Prostate; 2005 Nov 01; 65(3):203-15. PubMed ID: 15948138
    [Abstract] [Full Text] [Related]

  • 5. Combined low-dose imatinib mesylate and paclitaxel lack synergy in an experimental model of extra-osseous hormone-refractory prostate cancer.
    Corcoran NM, Costello AJ.
    BJU Int; 2005 Sep 01; 96(4):640-6. PubMed ID: 16104925
    [Abstract] [Full Text] [Related]

  • 6. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases.
    Uehara H, Kim SJ, Karashima T, Shepherd DL, Fan D, Tsan R, Killion JJ, Logothetis C, Mathew P, Fidler IJ.
    J Natl Cancer Inst; 2003 Mar 19; 95(6):458-70. PubMed ID: 12644539
    [Abstract] [Full Text] [Related]

  • 7. Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice.
    Weber KL, Doucet M, Price JE, Baker C, Kim SJ, Fidler IJ.
    Cancer Res; 2003 Jun 01; 63(11):2940-7. PubMed ID: 12782601
    [Abstract] [Full Text] [Related]

  • 8. Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production.
    Sweeney P, Karashima T, Kim SJ, Kedar D, Mian B, Huang S, Baker C, Fan Z, Hicklin DJ, Pettaway CA, Dinney CP.
    Clin Cancer Res; 2002 Aug 01; 8(8):2714-24. PubMed ID: 12171905
    [Abstract] [Full Text] [Related]

  • 9. Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer.
    Kim SJ, Uehara H, Yazici S, Busby JE, Nakamura T, He J, Maya M, Logothetis C, Mathew P, Wang X, Do KA, Fan D, Fidler IJ.
    J Natl Cancer Inst; 2006 Jun 07; 98(11):783-93. PubMed ID: 16757703
    [Abstract] [Full Text] [Related]

  • 10. Antivascular therapy of human follicular thyroid cancer experimental bone metastasis by blockade of epidermal growth factor receptor and vascular growth factor receptor phosphorylation.
    Younes MN, Yigitbasi OG, Park YW, Kim SJ, Jasser SA, Hawthorne VS, Yazici YD, Mandal M, Bekele BN, Bucana CD, Fidler IJ, Myers JN.
    Cancer Res; 2005 Jun 01; 65(11):4716-27. PubMed ID: 15930290
    [Abstract] [Full Text] [Related]

  • 11. The activity of zoledronic Acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation.
    Peng H, Sohara Y, Moats RA, Nelson MD, Groshen SG, Ye W, Reynolds CP, DeClerck YA.
    Cancer Res; 2007 Oct 01; 67(19):9346-55. PubMed ID: 17909043
    [Abstract] [Full Text] [Related]

  • 12. The bisphosphonate olpadronate inhibits skeletal prostate cancer progression in a green fluorescent protein nude mouse model.
    Yang M, Burton DW, Geller J, Hillegonds DJ, Hastings RH, Deftos LJ, Hoffman RM.
    Clin Cancer Res; 2006 Apr 15; 12(8):2602-6. PubMed ID: 16638872
    [Abstract] [Full Text] [Related]

  • 13. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
    Mori K, Le Goff B, Charrier C, Battaglia S, Heymann D, Rédini F.
    Bone; 2007 Apr 15; 40(4):981-90. PubMed ID: 17196895
    [Abstract] [Full Text] [Related]

  • 14. Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice.
    Lu S, Zhang J, Zhou Z, Liao ML, He WZ, Zhou XY, Li ZM, Xiang JQ, Wang JJ, Chen HQ.
    Oncol Rep; 2008 Sep 15; 20(3):581-7. PubMed ID: 18695909
    [Abstract] [Full Text] [Related]

  • 15. Effects of 12-O-tetradecanoylphorbol-13-acetate (TPA) in combination with paclitaxel (Taxol) on prostate Cancer LNCaP cells cultured in vitro or grown as xenograft tumors in immunodeficient mice.
    Zheng X, Chang RL, Cui XX, Avila GE, Hebbar V, Garzotto M, Shih WJ, Lin Y, Lu SE, Rabson AB, Kong AN, Conney AH.
    Clin Cancer Res; 2006 Jun 01; 12(11 Pt 1):3444-51. PubMed ID: 16740769
    [Abstract] [Full Text] [Related]

  • 16. Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor beta1-associated osteoblastic changes.
    Izumi K, Mizokami A, Li YQ, Narimoto K, Sugimoto K, Kadono Y, Kitagawa Y, Konaka H, Koh E, Keller ET, Namiki M.
    Prostate; 2009 Aug 01; 69(11):1222-34. PubMed ID: 19434660
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice.
    Lev DC, Kim SJ, Onn A, Stone V, Nam DH, Yazici S, Fidler IJ, Price JE.
    Clin Cancer Res; 2005 Jan 01; 11(1):306-14. PubMed ID: 15671560
    [Abstract] [Full Text] [Related]

  • 18. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors.
    Thaker PH, Yazici S, Nilsson MB, Yokoi K, Tsan RZ, He J, Kim SJ, Fidler IJ, Sood AK.
    Clin Cancer Res; 2005 Jul 01; 11(13):4923-33. PubMed ID: 16000591
    [Abstract] [Full Text] [Related]

  • 19. Smad3 is overexpressed in advanced human prostate cancer and necessary for progressive growth of prostate cancer cells in nude mice.
    Lu S, Lee J, Revelo M, Wang X, Lu S, Dong Z.
    Clin Cancer Res; 2007 Oct 01; 13(19):5692-702. PubMed ID: 17908958
    [Abstract] [Full Text] [Related]

  • 20. Effect of combination therapy with a novel bisphosphonate, minodronate (YM529), and docetaxel on a model of bone metastasis by human transitional cell carcinoma.
    Inoue K, Karashima T, Fukata S, Nomura A, Kawada C, Kurabayashi A, Furihata M, Ohtsuki Y, Shuin T.
    Clin Cancer Res; 2005 Sep 15; 11(18):6669-77. PubMed ID: 16166446
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.